cas 122-88-3|| where to buy 2-(4-Chlorophenoxy)acetic acid

Nom du produit:2-(4-Chlorophenoxy)acetic acid

IUPAC Name:2-(4-chlorophenoxy)acetic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM248374-1000g	1-2 Weeks	ǟǸƴ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 122-88-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:122-88-3; Formule moléculaire:C8H7ClO3; Point de fusion:-; Code SMILES:O=C(O)COC1=CC=C(Cl)C=C1; Densité:

: Numéro de catalogue:CM248374; Poids moléculaire:186.59; Point d'ébullition:315.2°C at 760 mmHg; N° Mdl:MFCD00004305; Stockage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: DNL343; Denali Therapeutics announces completion of enrollment for regimen G evaluating eIF2B agonist DNL343 in the phase 2/3 HEALEY ALS platform trial. Amyotrophic lateral sclerosis (ALS) causes progressive nerve degeneration in the spinal cord and brain, representing a large unmet medical need. The activation of integrated stress response (ISR) is documented in ALS patients, resulting in the suppression of eukaryotic translation initiation factor 2B (eIF2B) activity, and impaired protein synthesis.
Denali's ALS therapy DNL343 is an investigational small molecule eIF2B activator. It is designed to restore protein synthesis and inhibit ISR pathway in ALS. The compound is found to be generally well-tolerated and support once-daily dosing.